Allarity's Stenoparib Shows Colorectal Cancer Potential, Ovarian Cancer Survival Link at AACR
ALLR sits 57% above its 52-week low of $0.769.
Summary
Allarity Therapeutics presented two positive scientific posters at the AACR 2026 Annual Meeting, highlighting new data for its lead asset, stenoparib. The presentations showed stenoparib's potential in colorectal cancer by inhibiting growth of cell lines and modulating the WNT pathway, addressing a significant unmet medical need. Additionally, new data linked the company's proprietary DRP® companion diagnostic to enhanced overall survival in ovarian cancer patients treated with stenoparib, reinforcing the value of patient selection. This positive clinical update for a key pipeline asset is significant for the micro-cap biotech, following its recent 10-K which emphasized stenoparib as a strategic focus and a recent PRE 14A seeking a dilutive equity line. The data could bolster investor confidence in stenoparib's broad therapeutic potential and the DRP platform's utility. Investors will watch for further clinical trial advancements and regulatory updates for stenoparib in these indications.
At the time of this announcement, ALLR was trading at $1.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.8M. The 52-week trading range was $0.77 to $2.35. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.